{"id":959424,"date":"2026-05-07T01:03:20","date_gmt":"2026-05-07T05:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/"},"modified":"2026-05-07T01:03:20","modified_gmt":"2026-05-07T05:03:20","slug":"pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/","title":{"rendered":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <b>First quarter 2026 total revenues were US$72.4\u00a0million, an 8% decrease compared to the first quarter 2025<\/b>\n        <\/li>\n<li>\n          <b>RUCONEST\u00ae revenue was US$58.4\u00a0million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets<\/b>\n        <\/li>\n<li>\n          <b>Joenja\u00ae revenue was US$14.1\u00a0million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum<\/b>\n        <\/li>\n<li>\n          <b>Reaffirmed 2026 total revenue guidance of US$405 &#8211; US$425\u00a0million (8% &#8211; 13% growth)<\/b>\n        <\/li>\n<li>\n          <b>Generated positive net cash flow from operations of US$2.0\u00a0million in the quarter<\/b>\n        <\/li>\n<li>\n          <b>Joenja\u00ae\u202fapproved in Japan and received positive CHMP opinion for APDS<\/b>\n        <\/li>\n<li>\n          <b>Resubmitted pediatric sNDA to the FDA for Joenja\u00ae\u202f(leniolisib) for highest doses; plan additional sNDA this summer for lowest doses<\/b>\n        <\/li>\n<li>\n          <b>Pharming to host a conference call today at 13:30 CEST (7:30 am EDT)<\/b>\n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Leiden, the Netherlands, May 7, 2026: <\/b>Pharming Group N.V. (\u201cPharming\u201d or \u201cthe Company\u201d) (Euronext Amsterdam: PHARM \/ Nasdaq: PHAR) presents its preliminary unaudited financial report for the three months ended March 31, 2026.<\/p>\n<p align=\"justify\">\n        <b>Chief Executive Officer, Fabrice Chouraqui commented: <\/b><br \/>\n        <br \/>\n        <i>\u201cThe first quarter demonstrated important progress across the business while also reflecting revenue variability for RUCONEST\u00ae. Joenja\u00ae delivered strong revenue growth of 34% year over year, driven by robust patient uptake, reinforcing its role as an important growth driver still early in its lifecycle. We also made meaningful regulatory progress, including approval in Japan for APDS patients aged 4 and older and a positive CHMP opinion in Europe. In the U.S., constructive dialogue with the FDA following receipt of the CRL enabled us to already resubmit our pediatric sNDA for the two highest doses, which cover a meaningful proportion of children aged 4 to 11, and plan an additional sNDA submission for the lowest doses this summer.<\/i>\n      <\/p>\n<p align=\"justify\">\n        <i>First\u2011quarter RUCONEST\u00ae revenue was impacted by several factors we had largely anticipated and incorporated into our full-year guidance, notably specialty pharmacy inventory drawdowns and our strategic exit from non-U.S. markets. We continue to see the overwhelming majority of patients stay on RUCONEST\u00ae nine months after the launch of a new oral treatment. New patient enrollments and growing prescriber engagement further validate RUCONEST\u00ae\u2019s strong value proposition for high-burden patients.<\/i>\n      <\/p>\n<p align=\"justify\">\n        <i>We also advanced our key pipeline value drivers, including enrollment in the pivotal napazimone (KL1333) trial in primary mitochondrial disease and preparations for Phase II readouts later this year for leniolisib in broader primary immunodeficiencies. The encouraging compassionate-use experience with leniolisib in patients with CVID and immune dysregulation, which will be presented today at the Clinical Immunology Society Annual Meeting, further supports our view on the program\u2019s potential.<\/i>\n      <\/p>\n<p align=\"justify\">\n        <i>Finally, our focus on financial discipline also delivered tangible results, including positive net cash flow from operations in the quarter despite quarterly revenue variability. Taken together, our commercial execution, regulatory progress, pipeline advancement, and disciplined financial management position Pharming well for sustained long-term growth and value creation.\u201d<\/i>\n      <\/p>\n<p>\n        <b>First quarter 2026 highlights<\/b>\n      <\/p>\n<p>\n        <b>Commercialized products<\/b><br \/>\n        <br \/>\n        <b>RUCONEST\u00ae marketed for the treatment of acute HAE attacks<\/b>\n      <\/p>\n<p align=\"justify\">RUCONEST\u00ae revenue in the first quarter of 2026 was US$58.4\u00a0million, a 15% decrease compared to the first quarter of 2025. RUCONEST\u00ae revenue in the current quarter compared to the first quarter of 2025 was impacted by inventory drawdowns at U.S. specialty pharmacy customers, which were anticipated and reduced revenue by 8%, our previous decision to withdraw the product from non-U.S. markets, which reduced revenue by 3%, and competitive market dynamics in the U.S.<\/p>\n<p align=\"justify\">With its efficacy, reliability and rapid onset of action via IV administration, RUCONEST\u00ae remains a trusted on-demand treatment option for patients experiencing more severe or frequent attacks who have failed other on-demand medications. We continued to enroll new patients and add new prescribers in the quarter, with the vast majority of RUCONEST\u00ae patients showing limited interest in trialing or switching to alternative treatment options. Among patients who have trialed the new oral treatment option, we have observed that a meaningful proportion, particularly those experiencing more frequent attacks, have already made the decision to return to RUCONEST\u00ae.<\/p>\n<p>\n        <b>Joenja\u00ae (leniolisib) marketed for the treatment of APDS<\/b>\n      <\/p>\n<p align=\"justify\">Joenja\u00ae revenue increased to US$14.1\u00a0million in the first quarter of 2026, a 34% increase compared to the first quarter of 2025. Revenue growth was driven by a significant increase in patients on paid therapy in the U.S., offset by greater inventory drawdowns in the current quarter, and increased demand in international markets, including strong patient uptake in the U.K. following the April 2025 launch and significant growth in the number of patients on government-supported access programs.<\/p>\n<p align=\"justify\">The U.S. market contributed 82% of first quarter revenue, while the EU and Rest of World contributed 18%.<\/p>\n<p align=\"justify\">As of March 31, 2026, 127 patients were on paid therapy in the U.S., representing a 25% increase from the 102 patients at the end of the first quarter of 2025 and an increase of seven patients during the quarter.<\/p>\n<p>\n        <b>APDS patient finding<\/b>\n      <\/p>\n<p align=\"justify\">As of March 31, 2026, we have identified 1,016 diagnosed APDS patients of all ages globally, including 282 patients in the U.S. and 385 in core markets outside of the U.S. Of the identified patients in the U.S., 187 patients are 12 years of age or older and currently eligible for treatment with Joenja\u00ae, while 57 are between 4 and 11 years of age.<\/p>\n<p>\n        <b>Joenja\u00ae (leniolisib) development<\/b><br \/>\n        <br \/>\n        <b>Leniolisib for APDS<\/b>\n      <\/p>\n<p align=\"justify\">As of March 31, 2026, there are 180 APDS patients in either a leniolisib Expanded Access Program (compassionate use), an ongoing clinical study, or a paid access program.<\/p>\n<p>\n        <b>Pediatric label expansion <\/b>\n      <\/p>\n<p align=\"justify\">On January 30, 2026, we received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding our supplemental New Drug Application (sNDA) for Joenja\u00ae (leniolisib) for the treatment of APDS in children aged 4 to 11 years. <\/p>\n<p align=\"justify\">We held a Type A meeting with the FDA on March 26, 2026, to discuss the issues outlined in the letter and align on a path forward for resubmission. Upon the receipt of written feedback received from the FDA in the form of meeting minutes, we resubmitted the sNDA for the 40 mg and 50 mg twice-daily doses which would cover a meaningful proportion of the identified patient population, and plan to file a separate sNDA this summer for patients requiring a lower dose.<\/p>\n<p>\n        <b>European Economic Area (EEA)<\/b>\n      <\/p>\n<p align=\"justify\">On March 26, 2026, the CHMP adopted a positive opinion recommending marketing authorization for Joenja\u00ae (leniolisb) in adult and pediatric patients aged 12 years and older. A final decision by the European Commission (EC) on the marketing authorization is expected in the second quarter of 2026. <\/p>\n<p align=\"justify\">If approved, Joenja\u00ae would become the first approved treatment for APDS in the European Union. The centralized marketing authorization would be valid in all 27 European Union Member States, as well as Norway, Iceland and Liechtenstein.<\/p>\n<p>\n        <b>Japan<\/b>\n      <\/p>\n<p align=\"justify\">In March 2026, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted marketing authorization for Joenja\u00ae for the treatment of APDS in adult and pediatric patients aged 4 years and older. Joenja\u00ae is the first approved treatment for APDS in Japan and this approval is the first anywhere globally for children aged 4 to 11.<\/p>\n<p>\n        <b>Leniolisib for additional primary immunodeficiencies (PIDs)<\/b>\n      <\/p>\n<p align=\"justify\">Two Phase II clinical trials are evaluating leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, including genetically identifiable PIDs linked to altered PI3K\u03b4 signaling and common variable immunodeficiency or CVID, which represent substantially larger patient populations than APDS. Patient enrollment in both clinical trials is complete and we anticipate trial read-outs in the second half of 2026, consistent with prior guidance.<\/p>\n<p align=\"justify\">A presentation at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9, includes clinician expanded access experience with leniolisib to treat immune dysregulation in patients with CVID and CVID-like disorders. Clinician-reported outcomes demonstrated improvements, or no change or progression, in clinical manifestations of immune dysregulation and improvements in patients\u2019 quality of life.<\/p>\n<p>\n        <b>Organizational updates<\/b>\n      <\/p>\n<p align=\"justify\">On January 1, 2026, Leverne Marsh joined the Company as Chief Commercial Officer, succeeding Stephen Toor.<br \/><b>Financial summary<\/b><\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Consolidated Statement of Income<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2026<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <i>Amounts in US$m except per share data<\/i>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>72.4<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>79.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Cost of sales<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(6.6)<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(8.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Gross profit<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>65.8<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>70.8<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other income<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.4<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Research and development<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(25.6)<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(21.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">General and administrative<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(15.2)<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(22.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Marketing and sales<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(30.3)<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(34.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Other Operating Costs<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(71.1)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(78.2)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Operating profit (loss)<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4.9)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(7.0)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Finance result (net) and share of result in associates<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.2<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(4.8)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) before tax<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4.8)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(11.8)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income tax credit (expense)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.5)<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(3.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5.2)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(14.9)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Earnings per share<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Basic, attributable to equity holders of the parent (US$)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(0.007)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(0.022)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Diluted, attributable to equity holders of the parent (US$)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(0.007)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(0.022)<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Segment information &#8211; Revenues<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2026<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <i>Amounts in US$m<\/i>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Revenue &#8211; RUCONEST\u00ae (US)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">58.3<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">66.6<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Revenue &#8211; RUCONEST\u00ae (EU and RoW)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.1<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues &#8211; RUCONEST\u00ae<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>58.4<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>68.6<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Revenue &#8211; Joenja\u00ae (US)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">11.5<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">9.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Revenue &#8211; Joenja\u00ae (EU and RoW)<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2.5<\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues &#8211; Joenja\u00ae<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>14.1<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>10.5<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues &#8211; US<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>69.8<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>76.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues &#8211; EU and RoW<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>2.7<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>3.0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total Revenues<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>72.4<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>79.1<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Consolidated Balance Sheet<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>March 31, 2026<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>December 31, 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <i>Amounts in US$m<\/i>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Cash and cash equivalents, restricted cash and marketable securities<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>171.8<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>181.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Current assets<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>295.5<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>299.5<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Total assets<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>489.4<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>500.0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Current liabilities<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>112.3<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>115.8<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Shareholders&#8217; equity<\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>269.0<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>277.1<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Underlying figures are unrounded. Therefore, totals may differ slightly from the sum of individual items due to rounding effects in the presentation of this press release.<\/p>\n<p align=\"justify\">\n        <b>Financial highlights <\/b><br \/>\n        <br \/>For the first quarter of 2026, total revenues decreased by US$6.6\u00a0million, or 8%, to US$72.4\u00a0million, compared to US$79.1\u00a0million in the first quarter of 2025. RUCONEST\u00ae revenues amounted to US$58.4\u00a0million, a 15% decrease compared to the first quarter of 2025. This decrease in RUCONEST\u00ae revenues was primarily driven by volume decreases in the U.S. and internationally, following our decision to withdraw from all non-U.S. markets. Joenja\u00ae revenues amounted to US$14.1\u00a0million in the first quarter of 2026, a 34% increase compared to the first quarter of 2025. This increase in Joenja\u00ae revenues was primarily driven by an increase in volume.<\/p>\n<p align=\"justify\">Gross profit decreased by US$5.0\u00a0million or 7% to US$65.8\u00a0million (1Q 2025: US$70.8\u00a0million), mainly due to the decrease in revenues.<\/p>\n<p align=\"justify\">The operating loss amounted to US$4.9\u00a0million compared to an operating loss of US$7.0\u00a0million in the first quarter of 2025. Excluding US$7.8\u00a0million of non-recurring Abliva acquisition-related expenses, the first quarter of 2025 would have reflected adjusted operating profit of US$0.8\u00a0million. The adjusted operating profit declined due to the decrease in revenues, increased R&amp;D spending mainly related to the addition of napazimone (KL1333) to our pipeline, and unfavorable currency translation effects, partially offset by other expense savings.<\/p>\n<p align=\"justify\">The finance result (net) and share of result in associates amounted to a gain of US$0.2\u00a0million compared to a loss of US$4.8\u00a0million in the first quarter of 2025. This improvement was primarily driven by favorable EUR\/USD exchange rate movements, resulting in a foreign currency gain of US$2.4 million, compared to a loss of US$2.6 million in the first quarter of 2025.<\/p>\n<p align=\"justify\">In the first quarter of 2026, a net loss of US$5.2\u00a0million was realized, compared to a net loss of US$14.9\u00a0million in the first quarter of 2025. In addition to the aforementioned drivers, the net result was positively impacted by a lower tax expense of US$0.5\u00a0million compared to a tax expense of US$3.1\u00a0million in the first quarter of 2025.<\/p>\n<p align=\"justify\">Cash generated from operations amounted to US$2.0\u00a0million, compared to US$0.2\u00a0million in the first quarter of 2025. Cash and cash equivalents, including restricted cash and marketable securities, decreased from US$181.1\u00a0million at the end of fourth quarter of 2025 to US$171.8\u00a0million at the end of the first quarter of 2026. This decrease was primarily driven by a US$12.3\u00a0million settlement of the lease liability following the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands.<\/p>\n<p>\n        <b>Outlook\/Summary<\/b>\n      <\/p>\n<p align=\"left\">For 2026, the Company anticipates:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.<\/li>\n<li style=\"text-align:justify\">Total operating expenses between US$330 million and US$335 million (6% to 8% growth), including US$60 million incremental R&amp;D expenses to advance the pipeline and US$9 million structural G&amp;A cost reductions based on the plan announced in October 2025.<\/li>\n<li style=\"text-align:justify\">Continued RUCONEST\u00ae growth, and significant and accelerating Joenja\u00ae U.S. and ex-U.S. growth.<\/li>\n<li style=\"text-align:justify\">Progress towards additional regulatory approvals and commercial launches for leniolisib for APDS patients 12 years of age or older and for pediatric label expansion in key global markets.<\/li>\n<li style=\"text-align:justify\">Top-line data readouts for the two ongoing leniolisib Phase II clinical trials in PIDs with immune dysregulation to expand the asset\u2019s addressable patient population.<\/li>\n<li style=\"text-align:justify\">Completion of enrollment in the pivotal FALCON clinical study for napazimone (KL1333) in mitochondrial DNA-driven primary mitochondrial diseases.<\/li>\n<li style=\"text-align:justify\">Enhancing capital allocation to drive growth and build a leading global rare disease company.<\/li>\n<li style=\"text-align:justify\">Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases. Financing, if required, would come via a combination of our strong balance sheet and access to capital markets.<\/li>\n<\/ul>\n<p align=\"justify\">No further specific financial guidance for 2026 is provided.<\/p>\n<p>\n        <b>Additional information<\/b><br \/>\n        <br \/>\n        <i>Presentation<\/i>\n      <\/p>\n<p align=\"justify\">The conference call presentation is available on the Pharming.com website from 07:30 CEST today.<\/p>\n<p>\n        <i>Conference Call<\/i>\n      <\/p>\n<p align=\"justify\">The conference call will begin at 13:30 CEST \/ 07:30 EDT on Thursday, May 7. A transcript will be made available on the Pharming.com website in the days following the call.<\/p>\n<p align=\"justify\">\n        <i>Please note, the Company will only take questions from dial-in attendees.<\/i>\n      <\/p>\n<p>\n        <i>Webcast Link: <\/i>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NeSzAgU0QCMTKtvZDOFEzu3sbMjZyrznEZm5a6V2ETeRktYwhu03HS__ORnCHA53usx8EH7EEb_0RZiT0oy5AAVj4WlqRLjJbSO3bsGCgUOAkNpZEcbggTkUpVqpvmTb5IQ3TgNRePAHcHs_HJV4S9aDAkaKQnbRzp1snDhKj2k=\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/topu6hc2\/<\/a>\n      <\/p>\n<p>\n        <i>Conference call dial-in details: <\/i>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NeSzAgU0QCMTKtvZDOFEziwjBkhy3DTESsg6M_casZrr9YXeVzaZbqN3Ird9ZddGCBeDCWyu3204Y5ysx7ltgwi4nIJddjGNQMGPUQZovvlPRdQl0wf0MeiXDZf_kbfzknqO67B2NOhm7vNzWEhdla8KK1ElS7wVFQJcZPMDVFY5kGW3smtWs8WYg4iZnh_xVQY273xOh3uBydD6fVG6oF0XlAZVXaPDf1X5YbJvulAx37ru45YgVqNAS3oiCAic8UB88TAC0oR99O08OojnEw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/register-conf.media-server.com\/register\/BI1dba0cdf00fd47289729b51369140831<\/a>\n      <\/p>\n<p align=\"justify\">Additional information on how to register for the conference call\/webcast can be found on the<br \/>Pharming.com website.<\/p>\n<p>\n        <i>Financial Calendar 2026<\/i>\n      <\/p>\n<p align=\"justify\">Annual General Meeting of Shareholders \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0May 28<br \/>2Q\/1H 2026 financial results \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0July 30<br \/>3Q 2026 financial results\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0November 5<\/p>\n<p>\n        <b>For further public information, contact:<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>Investor Relations<\/b><br \/>\n        <br \/>Michael Levitan, VP Investor Relations and Capital Markets<br \/>T: +1 (908) 705 1696<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YoCgK21ABOQgII75Mg9QZdMDbZd8hG0O7lzah4SLLYsVLOYz6PzzlHHhZLvasGHPXKPvIWFvvfyGy6l5H72UBd0nfxpUD-O0281UR6mQ41Q=\" rel=\"nofollow\" target=\"_blank\">investor@pharming.com<\/a><\/p>\n<p align=\"justify\">\n        <b>Media Relations<\/b><br \/>\n        <br \/>Global: Saskia Mehring, Head of Corporate Communications<br \/>T: +31 6 28 32 60 41<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J2_L-2vR-ZqCRLXOJ5LUpZ2uID1ZCCqc2A4u_gzV-uNRDuauw5ihlxasuV2m469olDwZOtavGGfMnJ8C7q9bNZpmoiD4OWJ_EfDaE5oxNMiiyXOTyPrzN5mcgrJyQMrc\" rel=\"nofollow\" target=\"_blank\">media.relations@pharming.com<\/a><\/p>\n<p align=\"justify\">U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)<br \/>T: +1 (917) 882-9038<\/p>\n<p align=\"justify\">Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)<br \/>T: +31 6 53 81 64 27<\/p>\n<p>\n        <b>About Pharming Group N.V. <\/b>\n      <\/p>\n<p align=\"justify\">Pharming Group N.V. (EURONEXT Amsterdam: PHARM\/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations. <\/p>\n<p align=\"justify\">For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GKG1Ql8rb0a0KrYk_V9AqFiHTBaQ7IjFqejt3btuvfxRhgjkArLG32rExob25vxg_qNne2SPqsTMiG2JT5cXhpSL9pAvB-raV6S-Q6bz5Ow=\" rel=\"nofollow\" target=\"_blank\">www.pharming.com<\/a> and find us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VpWeRVQt2Zij0jXSfDcJKC8j5VHRVmZ1hWssIXsMXyh8reaFCP2alEmhFCVU3vOnesDri8uC6Fkpqx1Fbj1bGga9Y7n3aSJP9gKjmDscCow=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>. <\/p>\n<p>\n        <b>Forward-looking Statements <\/b>\n      <\/p>\n<p align=\"justify\">\n        <i>This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management\u2019s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as \u201caim\u201d, \u201cambition\u201d, \u2018\u2018anticipate\u2019\u2019, \u2018\u2018believe\u2019\u2019, \u2018\u2018could\u2019\u2019, \u2018\u2018estimate\u2019\u2019, \u2018\u2018expect\u2019\u2019, \u2018\u2018goals\u2019\u2019, \u2018\u2018intend\u2019\u2019, \u2018\u2018may\u2019\u2019, \u201cmilestones\u201d, \u2018\u2018objectives\u2019\u2019, \u2018\u2018outlook\u2019\u2019, \u2018\u2018plan\u2019\u2019, \u2018\u2018probably\u2019\u2019, \u2018\u2018project\u2019\u2019, \u2018\u2018risks\u2019\u2019, \u201cschedule\u201d, \u2018\u2018seek\u2019\u2019, \u2018\u2018should\u2019\u2019, \u2018\u2018target\u2019\u2019, \u2018\u2018will\u2019\u2019 and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming&#8217;s preclinical studies and clinical trials of its product candidates, Pharming&#8217;s clinical and commercial prospects, and Pharming&#8217;s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming&#8217;s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming&#8217;s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming&#8217;s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.<\/i>\n      <\/p>\n<p>\n        <b>Inside Information<\/b>\n      <\/p>\n<p align=\"justify\">\n        <i>This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.<\/i>\n      <\/p>\n<p>\n        <b>Pharming Group N.V.<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)<\/b><\/p>\n<p>For the period ended March 31, 2026<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Condensed consolidated statement of income<\/li>\n<li style=\"text-align:justify\">Condensed consolidated statement of comprehensive income<\/li>\n<li style=\"text-align:justify\">Condensed consolidated balance sheet<\/li>\n<li style=\"text-align:justify\">Condensed consolidated statement of changes in equity<\/li>\n<li style=\"text-align:justify\">Condensed consolidated statement of cash flow\n<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:467.25pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:395px;vertical-align: middle\">\n            <b>CONDENSED CONSOLIDATED STATEMENT OF INCOME<\/b>\n          <\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;vertical-align: top\">For the period ended March 31<\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Amounts in US$ \u2018000<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2026<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Revenues<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>72,447<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>79,094<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Costs of sales<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(6,644)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(8,323)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Gross profit<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>65,803<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>70,771<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Other income<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>377<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>383<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Research and development<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(25,557)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(21,142)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">General and administrative<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(15,217)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(22,486)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Marketing and sales<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(30,317)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(34,570)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Other Operating Costs<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(71,091)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(78,198)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Operating profit (loss)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4,911)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(7,044)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other finance income<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3,237<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">604<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other finance expenses<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(2,695)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(5,098)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Finance result, net<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>543<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4,494)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Share of net profits (loss) in associates using the equity method<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(385)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(250)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) before tax<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4,753)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(11,788)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income tax credit (expense)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(459)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(3,100)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,213)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(14,888)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Attributable to:<\/b>\n          <\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Equity holders of the parent<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,213)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(14,719)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Non-controlling interests<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(169)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Earnings per share<\/b>\n          <\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Basic, attributable to equity holders of the parent (US$)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.007)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.022)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Diluted, attributable to equity holders of the parent (US$)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.007)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.022)<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:467.25pt;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\" style=\"width:623px;vertical-align: middle\">\n            <b>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:623px;vertical-align: top\">For the period ended March 31<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Amounts in US$ \u2018000<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2026<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,213)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(14,888)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Currency translation differences<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,027)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">8,931<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Items that may be subsequently reclassified to profit or loss<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,027)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,931<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Other comprehensive income (loss), net of tax<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,027)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,931<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total comprehensive income (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(10,239)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,957)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Attributable to:<\/b>\n          <\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Equity holders of the parent<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(10,239)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,788)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Non-controlling interests<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(169)<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:394px;vertical-align: middle\">\n            <b>CONDENSED CONSOLIDATED BALANCE SHEET<\/b>\n          <\/td>\n<td style=\"width:115px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Amounts in US$ \u2018000<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>March 31, 2026<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>December 31, 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Non-current assets<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Intangible assets<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">130,988<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">135,538<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Property, plant and equipment<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">6,880<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">7,233<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Right-of-use assets<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">16,218<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">16,738<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Long-term prepayments<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">93<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">94<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Deferred tax assets<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">30,668<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">31,017<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Investment accounted for using the equity method<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">1,533<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">1,944<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Investment in debt instruments designated as at FVTPL<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">6,580<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">6,703<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Restricted cash<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">895<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">1,227<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total non-current assets<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>193,854<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>200,495<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Current assets<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Inventories<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">64,577<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">64,902<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Trade and other receivables<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">60,034<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">54,704<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Restricted cash<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">725<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">761<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Marketable securities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">117,796<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">33,796<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Cash and cash equivalents<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">52,379<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">145,305<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total current assets<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>295,511<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>299,469<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total assets<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>489,365<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>499,963<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Equity<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Share capital<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">8,065<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">8,009<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Share premium<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">518,601<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">513,257<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other reserves<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">23,749<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">28,819<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Accumulated deficit<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(281,455)<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(272,983)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Shareholders\u2019 equity<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>268,960<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>277,102<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Non-controlling interests<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total equity<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>268,960<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>277,102<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Non-current liabilities<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Convertible bonds<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">93,390<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">92,719<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Lease liabilities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">14,670<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">14,351<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total non-current liabilities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>108,060<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>107,070<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Current liabilities<\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Convertible bonds<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">5,375<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">5,336<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Provisions<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">675<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">1,187<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Trade and other payables<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">103,526<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">105,899<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Lease liabilities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">2,770<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">3,369<\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total current liabilities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>112,346<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>115,791<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:394px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total equity and liabilities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>489,365<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>499,963<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"width:624px;vertical-align: middle\">\n            <b>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"width:624px;vertical-align: top\">For the period ended March 31<\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"width:624px;vertical-align: top\">Attributable\u00a0to\u00a0owners\u00a0of\u00a0the\u00a0parent<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:56px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:60px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:80px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:68px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Amounts in US$ \u2018000<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Share capital<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Share premium<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Other reserves<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Accumulated deficit<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Non-controlling interests<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total equity<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Balance at January 1, 2025<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>7,769<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>488,990<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(209)<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(275,489)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>221,061<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>221,061<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Profit (loss) for the period<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(14,719)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(14,719)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(169)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(14,888)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other comprehensive income (loss) for the period<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">8,931<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">8,931<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">8,931<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total comprehensive income (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,931<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(14,719)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,788)<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(169)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,957)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other reserves<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(30)<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">30<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income tax benefit from excess tax deductions related to share-based payments<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(225)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(225)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(225)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Share-based compensation<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2,576<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2,576<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2,576<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Options exercised \/ LTIP shares issued<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">37<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1,311<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(3,512)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(2,164)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(2,164)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Acquisition of a subsidiary<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">5,869<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">5,869<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Acquisition of non-controlling interests<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1,462)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1,462)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(4,408)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,870)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total transactions with owners, recognized directly in equity<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>37<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1,311<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(30)<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(2,593)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(1,275)<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1,461<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>186<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Balance at March 31, 2025<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>7,806<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>490,301<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,692<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(292,801)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>213,998<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1,292<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>215,290<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:56px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:60px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:80px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:68px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:59px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Balance at January 1, 2026<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,009<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>513,257<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>28,819<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(272,983)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>277,102<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>277,102<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Profit (loss) for the period<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,213)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,213)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,213)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other comprehensive income (loss) for the period<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,027)<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,027)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5,027)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total comprehensive income (loss) for the period<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,027)<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(5,213)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(10,239)<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(10,239)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other reserves<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(44)<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">34<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(9)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(9)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income tax benefit from excess tax deductions related to share-based payments<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">339<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">339<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">339<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Share-based compensation<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3,225<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3,225<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3,225<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Options exercised \/ LTIP shares issued<\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">55<\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">5,344<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(6,858)<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1,458)<\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1,458)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total transactions with owners, recognized directly in equity<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>55<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>5,344<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(44)<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(3,259)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>2,097<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>2,097<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:183px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Balance at March 31, 2026<\/b>\n          <\/td>\n<td style=\"width:56px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>8,065<\/b>\n          <\/td>\n<td style=\"width:60px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>518,601<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>23,749<\/b>\n          <\/td>\n<td style=\"width:80px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(281,455)<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>268,960<\/b>\n          <\/td>\n<td style=\"width:68px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>\u2014<\/b>\n          <\/td>\n<td style=\"width:59px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>268,960<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:0pt;width:468pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:395px;vertical-align: middle\">\n            <b>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS<\/b>\n          <\/td>\n<td style=\"width:115px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;vertical-align: top\">For the period ended March 31<\/td>\n<td style=\"width:115px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Amounts in $\u2019000<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2026<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>1Q 2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Profit (loss) before tax<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(4,753)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>(11,788)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b><br \/>\n              <i>Adjustments to reconcile net profit (loss) to net cash used in operating activities:<\/i><br \/>\n            <\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Depreciation, amortization, impairment of non-current assets<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">3,116<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">2,582<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Equity settled share based payments<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">3,225<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">2,576<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Loss (gain) on disposal of leases<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">6<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other finance income<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(812)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(604)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other finance expenses<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">244<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">5,028<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Share of net losses (profits) in associates using the equity method<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">385<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">232<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Operating cash flows before changes in working capital<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>1,411<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>(1,970)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b><br \/>\n              <i>Changes in working capital:<\/i><br \/>\n            <\/b>\n          <\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Inventories<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(264)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(1,083)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Trade and other receivables<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(4,395)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">5,385<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Payables and other current liabilities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">5,285<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(2,857)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Provisions<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(512)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Restricted cash<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">331<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(26)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Total changes in working capital<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>445<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>1,419<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Interest received<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">379<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">737<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income taxes received (paid)<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(284)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">46<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Net cash flows generated from (used in) operating activities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>1,952<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>232<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Capital expenditure for property, plant and equipment<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(238)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(282)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Investment intangible assets<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Investment in associates using the equity method<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(411)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Purchases of marketable securities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(102,646)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">Proceeds from sale of marketable securities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">18,124<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">67,866<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">Acquisition of a subsidiary, net of cash acquired<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(57,476)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Net cash flows generated from (used in) investing activities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>(84,760)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>9,691<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Payment of lease liabilities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(12,975)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(715)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Interests on lease liabilities<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(125)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(275)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">Settlement of share based compensation awards<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">3,878<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">241<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">Acquisition of non-controlling interests<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(5,970)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Net cash flows generated from (used in) financing activities<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>(9,222)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>(6,719)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Increase (decrease) of cash<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>(92,031)<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>3,204<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Exchange rate effects<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">(895)<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">1,945<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Cash and cash equivalents at January 1<\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">145,305<\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">54,944<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:115px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:114px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:395px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Total cash and cash equivalents at March 31<\/b>\n          <\/td>\n<td style=\"width:115px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>52,379<\/b>\n          <\/td>\n<td style=\"width:114px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>60,093<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/2fbddcec-5a41-4647-ab73-c2f57f165f47\">Pharming Group reports 1Q26 results_EN_07MAY26<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NjMyYzZiNTAtYWI3NC00ODUzLTk1MDEtMGMzYTU3NmY3OTE5LTEwMTI1NDktMjAyNi0wNS0wNy1lbg==\/tiny\/Pharming-Group-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First quarter 2026 total revenues were US$72.4\u00a0million, an 8% decrease compared to the first quarter 2025 RUCONEST\u00ae revenue was US$58.4\u00a0million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets Joenja\u00ae revenue was US$14.1\u00a0million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum Reaffirmed 2026 total revenue guidance of US$405 &#8211; US$425\u00a0million (8% &#8211; 13% growth) Generated positive net cash flow from operations of US$2.0\u00a0million in the quarter Joenja\u00ae\u202fapproved in Japan and received positive CHMP opinion for APDS Resubmitted pediatric sNDA to the FDA for Joenja\u00ae\u202f(leniolisib) for highest doses; plan additional sNDA this summer for lowest doses Pharming to host a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959424","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"First quarter 2026 total revenues were US$72.4\u00a0million, an 8% decrease compared to the first quarter 2025 RUCONEST\u00ae revenue was US$58.4\u00a0million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets Joenja\u00ae revenue was US$14.1\u00a0million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum Reaffirmed 2026 total revenue guidance of US$405 &#8211; US$425\u00a0million (8% &#8211; 13% growth) Generated positive net cash flow from operations of US$2.0\u00a0million in the quarter Joenja\u00ae\u202fapproved in Japan and received positive CHMP opinion for APDS Resubmitted pediatric sNDA to the FDA for Joenja\u00ae\u202f(leniolisib) for highest doses; plan additional sNDA this summer for lowest doses Pharming to host a &hellip; Continue reading &quot;Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T05:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026\",\"datePublished\":\"2026-05-07T05:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/\"},\"wordCount\":3338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/\",\"name\":\"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\",\"datePublished\":\"2026-05-07T05:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/","og_locale":"en_US","og_type":"article","og_title":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk","og_description":"First quarter 2026 total revenues were US$72.4\u00a0million, an 8% decrease compared to the first quarter 2025 RUCONEST\u00ae revenue was US$58.4\u00a0million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets Joenja\u00ae revenue was US$14.1\u00a0million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum Reaffirmed 2026 total revenue guidance of US$405 &#8211; US$425\u00a0million (8% &#8211; 13% growth) Generated positive net cash flow from operations of US$2.0\u00a0million in the quarter Joenja\u00ae\u202fapproved in Japan and received positive CHMP opinion for APDS Resubmitted pediatric sNDA to the FDA for Joenja\u00ae\u202f(leniolisib) for highest doses; plan additional sNDA this summer for lowest doses Pharming to host a &hellip; Continue reading \"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T05:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026","datePublished":"2026-05-07T05:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/"},"wordCount":3338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/","name":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==","datePublished":"2026-05-07T05:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDQxOSM0MDIzODc5NTMjMjAwMDk3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja-u-s-pediatric-label-expansion-and-launches-in-japan-and-europe-in-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharming Group reports first quarter 2026 financial results; on track for Joenja\u00ae U.S. pediatric label expansion and launches in Japan and Europe in 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959424"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959424\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}